



Sponsored by



Please join us for an upcoming program

Patient Case Studies For The Pharmacological Management of Overactive Bladder

FACULTY

SHENELLE WILSON MD
Medical Director | Owner
Metro Atlanta Urology and Pelvic Health Center
Urologist | Urogynecologist

RSVP TO

Derrick Simon
+1 (774) 405-5504
derrick.simon@us.sumitomo-pharma.com

DATE/TIME

Thursday, September 17, 2026
6:15 PM (GMT-04:00) Eastern Daylight Time
(America/New_York)

LOCATION

Austin's Firegrill and Oyster Bar
2817 Old Dawson Road
Albany, Georgia
(229) 883-4482

RSVP BY

Please respond as soon as possible as space is limited 1-833-245-3178

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product. Hypersensitivity reactions, such as angioedema, have occurred.

WARNINGS AND PRECAUTIONS

Urinary Retention

Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction or patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.

Angioedema

Angioedema of the face and/or larynx has been reported with GEMTESA. Angioedema has been reported to occur hours after the first dose or

after multiple doses. Angioedema, associated with upper airway swelling, may be life-threatening. If involvement of the tongue, hypopharynx, or larynx occurs, immediately discontinue GEMTESA and provide appropriate therapy and/or measures necessary to ensure a patent airway.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 2\%$) reported with GEMTESA were headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection.

Please see accompanying full Prescribing Information.

